Compare Cytokinetics Inc (CYTK) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Main Street Capital Corporation — how do they compare? Cytokinetics Inc trades at $62.77 (market cap $8.62B), while Main Street Capital Corporation trades at $53.8 (market cap $5.09B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Main Street Capital Corporation pays a 5.84% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Main Street Capital Corporation for 89 Days on average.
| CYTK | MAIN | |
|---|---|---|
Market Cap | $8.62B | $5.09B |
Volume | 2,594,626 | 524,060 |
Sector | Health | Financials |
52-Week High | $87.26 | $64.60 |
52-Week Low | $54.76 | $49.63 |
Typical Hold Time | 19 Days | 89 Days |
Enterprise Value | $8.72B | $7.54B |
Dividend Yield | — | 5.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
MAIN trades at $54.15, down slightly over the past day. The stock shows mixed technical signals with a bearish overall trend but oversold short-term RSI. Fundamentally, the company maintains strong profitability with an 80.77% net margin and a P/E of 10.94, though revenue is expected to decline in 2026. Recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026.
The outlook is cautious. Analyst consensus is a Hold with a $58.33 price target, implying modest upside. Risks include softening earnings and negative operating cash flow. The dividend remains well-covered, supporting income investors, but growth prospects appear limited near-term amid a bearish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
